<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00607243</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_SPX_301</org_study_id>
    <secondary_id>CJ corporation</secondary_id>
    <nct_id>NCT00607243</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of CJ-50300 in Healthy Volunteers</brief_title>
  <official_title>Randomized, Double Blind, a Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of CJ-50300 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The currently available stock of smallpox vaccine would be insufficient in the face of an
      incident of smallpox attack. Thus, new manufacturing methods for smallpox vaccine are
      urgently needed because previous manufacturing methods using calf lymph are no longer
      acceptable in the view of current standards. Recently, CJ corporation in Republic of Korea
      has developed cell-culture derived smallpox vaccine (CJ-50300) which was manufactured by
      infecting MRC-5 cells. The aim of this clinical trial were to assess safety, reactogenicity,
      and immunogenicity of CJ-50300.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cutaneous Take Reaction</measure>
    <time_frame>7-9 day</time_frame>
    <description>The &quot;take reaction&quot;was defined as a vesicular or pustular lesion or an area of definite palpable induration or congestion surrounding a central lesion (a crust or ulcer) occurring at the vaccination site at any of post-vaccination days (PVDs) 6-8. The vaccination site was photographed, and measures were taken.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Reactions</measure>
    <time_frame>0-28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody Response</measure>
    <time_frame>14 or 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-mediate Immunity</measure>
    <time_frame>14 or 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Smallpox</condition>
  <arm_group>
    <arm_group_label>Conventional dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diluted CJ-50300 2.5 x 10000pfu/dose vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>smallpox vaccine CJ-50300</intervention_name>
    <description>Conventional dose group: 2.5 x 10 5 pfu/dose Diluted dose group:2.5 x 10 4 pfu/dose</description>
    <arm_group_label>Conventional dose group</arm_group_label>
    <arm_group_label>Low dose group</arm_group_label>
    <other_name>CJ-53300</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy Korean male and female subjects between 20 and 60 years of age at the time of
             screening visit

          2. Willing to participate and have signed the informed consent form

          3. In good general health, without clinically skin diseases history, physical examination
             or laboratory test results

          4. Hematocrit &gt; 33% for women; &gt; 38% for men

          5. White cell count 3,300-12,000/mm3

          6. Total lymphocyte count &gt; 800 cells/mm3

          7. Subjects who have never been vaccinated with smallpox vaccines

        Exclusion Criteria:

          1. Diseases or conditions that cause immunodeficiency (For examples; HIV AIDS, leukemia,
             lymphoma, generalized malignancy, agammaglobulinemia, history of transplantation,
             therapy with alkylating agents, antimetabolites, radiation, or oral or parenteral
             corticosteroids).

          2. In close physical contact (household or at work) with an individual who has the
             diseases or conditions that cause immunodeficiency

          3. History or present of eczema or atopic dermatitis

          4. Allergy or sensitivity to any known components of vaccine or other medicines

          5. In close physical contact (household or at work) with an individual who has acute or
             chronic skin conditions such as dermatitis, exfoliative dermatitis

          6. Subjects requiring steroid therapy

          7. Subjects who are taking immunosuppressive therapy

          8. Subjects who are planning for blood donations

          9. Autoimmune disease such as lupus erythematosus

         10. Subjects who work in medical institution

         11. Household contacts with women who are pregnant or breast-feeding

         12. Female subjects who are pregnant or breast-feeding and have positive result by serum
             pregnancy test or urine pregnancy test, or do not using approved contraceptives such
             as sterilization, contraceptive ring injectable, combined oral contraceptive pills and
             barrier contraceptive, combined hormone-based therapy, contraceptive cream,
             contraceptive jelly, diaphragm or condoms

         13. Subjects household member &lt; 1 year old or work with children &lt; 1 year old

         14. Subjects with a known history of Cardiac disease or have three or more of the
             following risk factors: hyperpiesia, obesity, hyperlipidemia, glucosuria, sclerosis,
             cerebral arteriosclerosis

         15. Receipt of immunoglobulin and steroid within 14 days of vaccination

         16. Receipt of investigational research agents within 120 days of vaccination

         17. HBsAg seropositive

         18. HCV antibody seropositive

         19. HIV seropositive

         20. Subjects having fever (oral temperature &gt; 38℃) or severe nutrition disorder

         21. Blood donation within 12 weeks in advance screening visit

         22. Subject who are not suitable to participate in study according to investigator's
             judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myoung-don Oh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2008</study_first_submitted>
  <study_first_submitted_qc>February 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2008</study_first_posted>
  <results_first_submitted>August 2, 2011</results_first_submitted>
  <results_first_submitted_qc>July 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 9, 2013</results_first_posted>
  <last_update_submitted>July 7, 2013</last_update_submitted>
  <last_update_submitted_qc>July 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Myoung-don Oh</investigator_full_name>
    <investigator_title>Professor, Division of Infectious Diseases, Department of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Smallpox vaccine efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Smallpox</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Conventional-dose Group</title>
          <description>Conventional CJ-50300 2.5 x 100000pfu/dose vaccination</description>
        </group>
        <group group_id="P2">
          <title>Low-dose Group</title>
          <description>Diluted CJ-50300 2.5 x 10000pfu/dose vaccination</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Initial Post-vaccination Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Telephone Safety Assessment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77">80 Available for 3 months 77 Available for 6 months</participants>
                <participants group_id="P2" count="39">40 Available for 3 months 39 Available for 6 months</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Conventional-dose Group</title>
          <description>Conventional CJ-50300 2.5 x 100000pfu/dose vaccination</description>
        </group>
        <group group_id="B2">
          <title>Low-dose Group</title>
          <description>Diluted CJ-50300 2.5 x 10000pfu/dose vaccination</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="123"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.9" spread="2.1"/>
                    <measurement group_id="B2" value="24.3" spread="2.8"/>
                    <measurement group_id="B3" value="24.0" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cutaneous Take Reaction</title>
        <description>The “take reaction”was defined as a vesicular or pustular lesion or an area of definite palpable induration or congestion surrounding a central lesion (a crust or ulcer) occurring at the vaccination site at any of post-vaccination days (PVDs) 6–8. The vaccination site was photographed, and measures were taken.</description>
        <time_frame>7-9 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional-dose Group</title>
            <description>Conventional CJ-50300 2.5 x 100000pfu/dose vaccination</description>
          </group>
          <group group_id="O2">
            <title>Low-dose Group</title>
            <description>Diluted CJ-50300 2.5 x 10000pfu/dose vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Cutaneous Take Reaction</title>
          <description>The “take reaction”was defined as a vesicular or pustular lesion or an area of definite palpable induration or congestion surrounding a central lesion (a crust or ulcer) occurring at the vaccination site at any of post-vaccination days (PVDs) 6–8. The vaccination site was photographed, and measures were taken.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="0.93" upper_limit="0.99"/>
                    <measurement group_id="O2" value="41" lower_limit="0.90" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Reactions</title>
        <time_frame>0-28 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Response</title>
        <time_frame>14 or 28 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cell-mediate Immunity</title>
        <time_frame>14 or 28 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days, 3 months, 6 months</time_frame>
      <desc>In the Conventional-dose Group, all 82 finished the 28 day follow up, 80 were available for 3 months, and 77 were available for the 6 months safety assessment.
In the Low-dose Group, all 41 finished the 28 day follow up, 40 were available for 3 months, and 39 were available for the 6 months safety assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Conventional-dose Group</title>
          <description>Conventional CJ-50300 2.5 x 100000pfu/dose vaccination</description>
        </group>
        <group group_id="E2">
          <title>Low-dose Group</title>
          <description>Diluted CJ-50300 2.5 x 10000pfu/dose vaccination</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Chill</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pain at vaccination site</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Axillary pain or lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Satellite lesion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>the study was limited to vaccinia-naïve adults, thus yielding no data concerning the efﬁcacy of CJ-50300 in non-naïve adults or in children.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Myoung-don Oh, M.D.</name_or_title>
      <organization>Seoul National University Hospital</organization>
      <phone>+82-2-2072-2945</phone>
      <email>mdohmd@snu.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

